The FINANCIAL — Bayer HealthCare and Regeneron Pharmaceuticals, Inc. today announced that they have initiated a Phase III clinical trial evaluating the efficacy and safety of VEGF Trap-Eye in the neovascular form of age-related macular degeneration in China.
The new trial, named SIGHT, will include approximately 300 patients and will be the largest retinal trial conducted in China. SIGHT is being led by Bayer.
Discussion about this post